PARP inhibition in the ovarian cancer patient: Current approvals and future directions

Katherine C. Kurnit, Monica Avila, Emily M. Hinchcliff, Robert L. Coleman, Shannon N. Westin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as biomarker-wildtype tumors. They have also gained momentum not only as a treatment strategy, but as a maintenance strategy as well. While PARP inhibitors were initially ev aluated in the recurrent setting, they have now moved to frontline therapy. This review will discuss the current FDA indications of the clinically available PARP inhibitors for treatment and maintenance therapies. We will then review the recently completed and ongoing clinical trials which may inform future clinical approvals.

Original languageEnglish (US)
Article number107588
JournalPharmacology and Therapeutics
StatePublished - Sep 2020


  • Clinical trials
  • Ovarian cancer
  • PARP inhibitors
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'PARP inhibition in the ovarian cancer patient: Current approvals and future directions'. Together they form a unique fingerprint.

Cite this